Discontinued — last reported Q4 '20
McKesson Litigation settlement gain (loss) decreased by 100.0% to $0.00 in Q4 2025 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Litigation settlement gain (loss) shows an upward trend with a -65.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Gains improve short-term net income, while losses represent a one-time hit to profitability and potential reputational or operational risk.
This metric captures the financial impact of legal settlements, including damages paid or received, and legal fees assoc...
Highly variable across companies; usually treated as an 'extraordinary' or 'non-recurring' item in financial analysis.
is_pfe_litigation_settlement_gain_loss| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$74.00M | -$112.00M | -$7.00M | -$279.00M | -$5.00M | $9.00M | $1.00M | $6.00M | $0.00 | $2.00M | $0.00 | -$39.00M | -$112.00M | $4.00M | $0.00 | -$110.00M | $0.00 | $2.00M | $0.00 |
| QoQ Change | — | -51.4% | +93.8% | <-999% | +98.2% | +280.0% | -88.9% | +500.0% | -100.0% | — | -100.0% | — | -187.2% | +103.6% | -100.0% | — | +100.0% | — | -100.0% |
| YoY Change | — | — | — | — | +93.2% | +108.0% | +114.3% | +102.2% | +100.0% | -77.8% | -100.0% | -750.0% | — | +100.0% | — | -182.1% | +100.0% | -50.0% | — |
| Segment | Q2 '24 |
|---|---|
| U.S. Pharmaceutical | -$57.00M |
| Total | -$112.00M |
U.S. Pharmaceutical was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | FY'25 |
|---|---|
| North American Pharmaceutical Segment and Corporate Expenses | $57.00M |
| Total | -$108.00M |
All segment values are derived from annual filings.